HM17321 Promotes High-Quality Weight Loss and Improves Metabolic Health in Obesity Treatment

Efficacy and Safety of HM15275, a Novel Long-Acting Triple Agonist in Adults With Obesity

Discovery of HM17321: A Novel CRFR2 Selective and Biased UCN2 Analog for High-Quality Weight Loss

Blood and Muscle Proteomic Analysis Reveals Muscle-Preserving Effects of HM17321 in Mouse Model

Identifying predictive biomarkers for HM16390, a novel long-acting IL-2 analog, by analyzing single -cell and bulk transcriptomic data of immune checkpoint inhibitors treated patients

A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390, as a Single Agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors

HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ and optimal IL-2Rα bindings, promotes peripheral Treg expansion to mitigate systemic toxicity while preserving potent anti-tumor immunity

HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ binding and optimal IL-2Rα binding, selectively expands tumor-specific T cells, resulting in potent anti-tumor immunity in murine tumor models